FDA Accepts BLA For Sanofi-Aventis Combination Vaccine Pentacel
This article was originally published in The Pink Sheet Daily
Executive Summary
Pentacel would be the first combination vaccine in the U.S. to protect against diphtheria, tetanus, pertussis, polio and Hib.
You may also be interested in...
Sanofi Pentacel Revised Action Date Is Nov. 2
FDA extends the combination vaccine’s action date for the second time, this time requesting lab validation information relating to the pertussis component, but not directly related to Pentacel.
Sanofi Pentacel Revised Action Date Is Nov. 2
FDA extends the combination vaccine’s action date for the second time, this time requesting lab validation information relating to the pertussis component, but not directly related to Pentacel.
Acambis’ Smallpox Vaccine Could See Approval As Soon As First Half 2007
An FDA “complete response” letter for the cell-based vaccine cites both clinical and CMC sections of the BLA, firm tells “The Pink Sheet” DAILY.